




Feidhmeannacht na Seirbhíse Sláinte
Health Service Executive

Mid-Western Regional Hospitals Complex
St. Camillus and St. Ita's Hospitals



Preferred DRUGS LIST

First Edition 2007

CONTENTS

page

Introduction	2
Gastrointestinal System	3
Cardiovascular System	4
Respiratory System	6
Central Nervous System	6
Infections	8
Endocrine System	10
Urinary-tract disorders	11
Malignant disease and immunosuppression	11
Nutrition and blood	11
Musculoskeletal and joint diseases	12
Skin	12
Application for inclusion of a medicine on Preferred List	13

Introduction

PREFERRED LIST

This is the preferred list of drugs for the Mid-Western Regional Hospitals Complex, St Camillus and St. ITA's Hospitals.

The compilation of the list has as its key influences: -

- a) The evidence base
- b) Hospital & specialty usage

It includes drugs in almost all therapeutic classes but by its nature includes only preferred drugs in each of these classes. The *Preferred List* is not a hospital formulary. The hospital formulary is the BNF, however, it is expected that the preferred list will influence prescribing with a view to:

- a) Promoting rational prescribing
- b) Facilitating safe prescribing
- c) Promoting efficient clinical pharmacy

Prescribing can take place outside of the *Preferred List* particularly in specialty areas e.g. oncology, ITU, CCU Rheumatology. However, we would like in so far as is practicable to encourage prescribing which adheres to the list.

The list is dynamic and will be altered on a 6 monthly basis by the Drugs & Therapeutics Committee to reflect best prescribing practice. Any consultant or senior pharmacist can recommend changes to the list.

Proposed changes should be communicated to the Chairman of the Drugs & Therapeutics Committee, Pharmacy Dept, Mid-Western Regional Hospital.

Preferred list amendment forms are available as postable cards at the back of this booklet. The committee will consider all submissions. We hope that you find the list helpful and look forward to your co-operation in its implementation.

Professor Declan Lyons
Chairman Drugs & Therapeutics Committee

Ms Elaine Murphy
A/Network Manager

Date: March 2007

Gastrointestinal System

DRUG NAME		
1.1 Dyspepsia & Gastro – oesophageal reflux disease		
1.1.1	Antacids	Magnesium hydroxide, dried aluminium hydroxide (Maalox liquid®)
1.1.2	Compound alginates	Sodium alginate, sodium bicarbonate, calcium carbonate (Gaviscon Liquid®)
1.2 Antispasmodics & other drugs altering gut motility		
	Antimuscarinic	Atropine Sulphate
		Hyoscine Butyl Bromide
	Directly-acting intestinal smooth muscle anti-spasmodic	Mebeverine
1.3 Ulcer-healing Drugs		
1.3.3	Mucosal Protectant Complex	Sucralfate
1.3.5	Proton Pump Inhibitors	Omeprazole
		Lansoprazole
1.4 Acute Diarrhoea		
1.4.2	Antimotility drugs	Codeine Phosphate
		Loperamide
1.5 Chronic Bowel disorders		
	Aminosalicylates	Mesalazine
		Sulphasalazine
	Corticosteroids	Budesonide
		Hydrocortisone Rectal
		Prednisolone Rectal
	Cytokine inhibitors	Infliximab
1.6 Laxatives		
1.6.1	Bulk-forming laxatives	Ispaghula Husk
1.6.2	Stimulant laxatives	Bisacodyl
		Co-danthramer
		Senna

		DRUG NAME
1.6.4	Osmotic laxatives	Lactulose
		Macrogols (polyethylene glycol) Movicol®
		Phosphate enema
		Sodium Citrate (Rectal) Microlax®
1.6.5	Bowel cleansing solutions	Fleet Phos-pho Soda®
		Klean prep®
1.9	Drugs affecting intestinal secretions	
1.9.4	Pancreatin	Pancreatin

Cardiovascular System

2.1	Positive inotropic drugs	
2.1.1	Cardiac glycosides	Digoxin
2.2	Diuretics	
2.2.1	Thiazides and related diuretics	Bendroflumethiazide
		Metolazone (unlicensed)
2.2.2	Loop diuretics	Furosemide
		Bumetanide
2.2.3	Potassium-sparing diuretics and Aldosterone antagonists	Spironolactone
		Amiloride
2.2.4	Potassium-sparing diuretics with other diuretics	Co-amilorfruse
2.3	Anti-arrhythmic drugs	
2.3.2	Drugs for arrhythmias	Adenosine
		Amiodarone
		Propafenone
		Flecainide
		Lidocaine
		Sotalol
2.4	Beta-adrenoceptor blocking drugs	
	Non-selective Beta-Blocker	Propranolol
	Selective Beta-blocker	Atenolol
		Bisoprolol

DRUG NAME		
2.5 Hypertension and heart failure		
2.5.1	Vasodilator antihypertensive drugs	Hydralazine
2.5.2	Centrally acting antihypertensive drugs	Methyldopa
2.5.4	Alpha-adrenoceptor blocking drugs	Doxazosin
2.5.5.1	Angiotensin-converting enzyme inhibitors	Captopril
		Perindopril
		Ramipril
2.5.5.2	Angiotensin-II receptor antagonists	Losartan
		Candesartan
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs		
2.6.1	Nitrates	Glyceryl trinitrate
		Isosorbide dinitrate
		Isosorbide mononitrate
2.6.2	Calcium-channel blockers	Amlodipine
		Diltiazem
		Verapamil
2.6.3	Potassium-channel activator	Nicorandil
2.6.4	Peripheral vasodilators and related drugs	Pentoxifylline (oxpentifylline)
2.7 Sympathomimetics		
2.7.1	Inotropic sympathomimetics	Dobutamine
		Dopamine
2.8 Anticoagulants		
2.8.1	Parenteral anticoagulants	Heparin
		Tinzaparin
		Enoxaparin
2.8.2	Oral anticoagulants	Warfarin
2.9 Antiplatelet drugs		
	Salicyclates	Aspirin
	Adenosine diphosphate (ADP) inhibitor	Clopidogrel

DRUG NAME		
	Inhibitor of platelet adhesion and aggregation	Dipyridamole
2.10	Myocardial infarction and fibrinolysis	
2.10.2	Fibrinolytic drugs	Retepase
2.12	Lipid-regulating drugs	
	HMG CoA reductase inhibitor	Atorvastatin
		Pravastatin

Respiratory System

3.1	Bronchodilators	
3.1.1.1	Selective Beta ₂ Agonists	Salbutamol
		Salmeterol
3.1.2	Antimuscarinic bronchodilators	Ipratropium Bromide
		Tiotropium
3.1.3	Theophylline	Theophylline
		Amionphylline
3.2	Corticosteroids	
	Inhaled corticosteroids	Beclometasone
		Fluticasone
3.3	Leukotriene receptor antagonists	
3.3.2	Leukotriene receptor antagonists	Montelukast

Central Nervous System

4.1	Hypnotics and anxiolytics	
4.1.1	Hypnotics	
	Benzodiazepines	Temazepam
	Benzodiazepine-related drug	Zopiclone
	Indirectly-acting GABA receptor agonist	Clomethiazole
4.1.2	Anxiolytics	
	Benzodiazepines	Alprazolam
		Diazepam
		Chlordiazepoxide
		Lorazepam

DRUG NAME		
4.2 Drugs used in psychoses and related disorders		
4.2.1	Antipsychotic drugs	Haloperidol
		Quetiapine
		Olanzapine
		Risperidone
4.2.3	Antimanic drugs	Lithium carbonate
		Lithium citrate
4.3 Antidepressant drugs		
4.3.1	Tricyclic antidepressants	Amitriptyline
		Lofepramine
		Trazadone
4.3.3	Selective serotonin re-uptake inhibitors	Citalopram
		Paroxetine
4.3.4	Noradrenergic and specific Serotonergic antidepressant	Mirtazapine
	Serotonin & Noradrenaline Re-uptake Inhibitors	Venlafexine
4.6 Drugs used in nausea and vertigo		
	Dopamine antagonists	Domperidone
		Metoclopramide
	5HT ₃ antagonists	Ondansetron
	Histamine analog	Betahistine
4.7 Analgesics		
4.7.1	Non-opioid analgesics	Paracetamol
	Compound analgesic preparations	Co-codamol
		Maxilief® (Co-codamol 500/8)
		Kapake® (Co-codamol 500/30)
4.7.2	Opioid analgesic	Tramadol
4.7.4.1	Treatment of acute migraine attack	
	5HT ₁ agonists	Sumatriptan
4.7.4.2	Prophylaxis of migraine	Pizotifen

DRUG NAME		
4.8	Antiepileptics	
4.8.1	Control of epilepsy	Carbamazepine
		Levetiracetam
		Lamotrigine
		Phenytoin
		Sodium valproate
		Topiramate
4.8.2	Drugs used in status epilepticus	Paraldehyde
4.9	Drugs used in parkinsonism and related disorders	
4.9.1	Dopaminergic drugs used in Parkinsonism	
	Levodopa with dopa-decarboxylase inhibitor	Co-beneldopa
		Co-careldopa
	NMDA receptor antagonist	Amantadine
	COMT Inhibitor	Entacapone
	Dopamine receptor agonists	Ropinirole
4.9.3.	Drugs used in essential tremor, chorea, tics & related disorders	Tetrabenazine
4.10	Drugs used in substance dependence	
	Alcohol dependence	Acamprosate
	Nicotine replacement therapies	Nicotine
4.11	Drugs for dementia	
	Acetylcholinesterase inhibitor	Donepezil
	NMDA receptor antagonist	Memantine

Infections

5.1	Antibacterial drugs	
5.1.1	Penicillins	
5.1.1.1.1	Penicillins	Benzylpenicillin
		Phenoxyethylpenicillin
5.1.1.2	Penicillinase-resistant penicillins	Flucloxacillin
5.1.1.3	Broad-spectrum penicillins	Amoxicillin
		Co-amoxiclav
5.1.1.4	Anti-pseudomonal penicillins	Piperacillin with tazobactam

DRUG NAME		
5.1.2	Cephalosporins	Cefradine
		Ceftazidime
		Ceftriaxone
		Cefuroxime (surgical Prophylaxis)
	Carbapenems	Meropenem
5.1.3	Tetracyclines	Doxycycline
5.1.4	Aminoglycosides	Gentamicin
5.1.5	Macrolides	Clarithromycin
5.1.6	Lincosamides	Clindamycin
5.1.7	Bacterial protein synthesis inhibitors	Chloramphenicol (unlicensed)
		Sodium fusidate
	Glycopeptides	Vancomycin
		Teicoplanin
5.1.8	Dihydrofolate reductase inhibitors	Trimethoprim
5.1.9	Antituberculous drugs	Rifater®
		Rifinah®
		Ethambutol
5.1.11	Nitroimidazole	Metronidazole
5.1.12	Quinolones	Ciprofloxacin
		Levofloxacin
5.1.13	5-nitrofurans	Nitrofurantoin
5.2	Antifungal drugs	
	Imidazoles	Fluconazole
		Itraconazole
		Voriconazole
	Polyene antifungals	Nystatin
5.3	Antiviral drugs	
5.3.2	Herpesvirus infection	Aciclovir
		Valaciclovir

DRUG NAME		
5.4	Antiprotozoal drugs	
5.4.1	Antimalarials	Chloroquine (oral)
		Quinine
5.5	Anthelmintics	
5.5.1	Drugs for threadworms	Mebendazole

Endocrine System

6.1	Drugs used in Diabetes	
6.1.1	Insulins	
6.1.1.1	Short-acting insulins	Soluble insulin (Actrapid®)
		Insulin Aspart (Novorapid®)
6.1.1.2	Intermediate & long-acting insulins	Insulin Detemir (Levemir®)
		Insulin Glargine (Lantus®)
		Isophane insulin (Insulatard®)
	Biphasic Insulin	Biphasic Isophane Insulin (Mixtard 30®)
		Biphasic Insulin Aspart (Novomix 30®)
6.1.2.1	Sulphonylureas	Glicazide
		Glimepiride
6.1.2.2	Biguanides	Metformin
6.1.2.3	Intestinal Alpha glucosidases inhibitor	Acarbose
	Thiazolidinediones	Rosiglitazone
6.1.4	Treatment of hypoglycaemia	Glucagon
6.2	Thyroid and antithyroid drugs	
6.2.1	Thyroid hormones	Levothyroxine
6.2.2	Antithyroid drugs	Carbimazole
6.3	Corticosteroids	
6.3.1	Replacement therapy	Fludrocortisone
		Hydrocortisone

DRUG NAME		
6.3.2	Glucocorticoid therapy	Prednisolone
		Dexamethasone
6.4	Sex hormones	
6.4.1.1	Oestrogens	Ethinylestradiol
	SERMS	Raloxifene
6.4.1.2	Progestogens	Medroxyprogesterone
6.4.2	5-alpha-reductase inhibitor	Finasteride
6.5	Hypothalamic and pituitary hormones and anti-oestrogens	
6.5.2	Posterior pituitary hormones and antagonists	Vasopressin
		Desmopressin
6.6.2	Bisphosphonates	Alendronate
		Risedronate

Urinary-tract disorders

7.4.1	Drugs for Urinary Retention	
	Alpha Blockers	Alfuzosin
		Tamsulosin
7.4.2	Drugs for urinary frequency, enuresis and incontinence	Tolterodine

Malignant disease and immunosuppression

8.3.4	Hormone antagonist	
8.3.4.1	Oestrogen receptor antagonists	Tamoxifen
	Aromatase inhibitors	Anastrozole
8.3.4.2	Gonadorelin analogues	Goserelin
	Anti-androgens	Cyproterone acetate

Nutrition and blood

9.1	Anaemias	
9.1.1.1	Oral iron	Ferrous sulphate
9.1.2	Drugs used in megaloblastic Anaemias	Hydroxocobalamin
		Folic acid
9.6	Vitamins	
9.6.2	Vitamin B group	Thiamine

DRUG NAME		
		Pyridoxine
9.6.4	Vitamin D (with calcium)	Calcium carbonate & colecalciferol (Calcichew D ₃ Forte®, Osteofos D ₃ ®)
9.6.6	Vitamin K	Phytomenadione

Musculoskeletal and joint diseases

10.1 Drugs used in rheumatic diseases and gout		
10.1.1	Non-steroidal anti-inflammatory Drugs	Diclofenac
		Etoricoxib
10.1.3	Drugs which suppress the rheumatic disease process	Methotrexate
		Sulfasalazine
10.1.4	Gout and cytotoxic-induced hyperuricaemia	Colchicine
	Hyperuricaemia	Allopurinol
10.2 Drugs used in neuromuscular disorders		
10.2.1	Drugs which enhance Neuromuscular transmission	Neostigmine
10.2.2	Skeletal muscle relaxants	Baclofen
		Tizanidine

Skin

13.4 Topical corticosteroids		
		Hydrocortisone
		Betamethasone (inc ready dilute)
		Clobetasol propionate
13.5 Preparations for eczema and psoriasis		
13.5.2	Preparations for psoriasis	Calcipotriol
		Coal tar
13.10 Anti-infective skin preparations		
13.10.1.1	Anti-bacterial preparations only used topically	Silver sulfadiazine
13.10.4	Parasiticial prepartions	Permethrin

**Application for inclusion of
a medicine on Preferred List**

Date:

Name of Consultant / Senior Pharmacist submitting the application:

Speciality Interest:

Information regarding the new drug

Therapeutic classification	
Generic Name	
Trade Name	
Manufacturer	
Dosage Form	

Briefly explain the advantages of this drug over those listed on the preferred list:

State which drug(s) on the preferred list this new drug could replace:

**Chairman of Drugs and Therapeutics Committee
Department of Pharmacy
Mid-Western Regional Hospital
Dooradoyle
Limerick**

Application for inclusion of a medicine on Preferred List

Date:

Name of Consultant / Senior Pharmacist submitting the application:

Speciality Interest:

Information regarding the new drug

Therapeutic classification	
Generic Name	
Trade Name	
Manufacturer	
Dosage Form	

Briefly explain the advantages of this drug over those listed on the preferred list:

State which drug(s) on the preferred list this new drug could replace:

**Chairman of Drugs and Therapeutics Committee
Department of Pharmacy
Mid-Western Regional Hospital
Dooradoyle
Limerick**

Application for inclusion of a medicine on Preferred List

Date:

Name of Consultant / Senior Pharmacist submitting the application:

Speciality Interest:

Information regarding the new drug

Therapeutic classification

Generic Name

Trade Name

Manufacturer

Dosage Form

Briefly explain the advantages of this drug over those listed on the preferred list:

State which drug(s) on the preferred list this new drug could replace:

**Chairman of Drugs and Therapeutics Committee
Department of Pharmacy
Mid-Western Regional Hospital
Dooradoyle
Limerick**

Application for inclusion of a medicine on Preferred List

Date:

Name of Consultant / Senior Pharmacist submitting the application:

Speciality Interest:

Information regarding the new drug

Therapeutic classification	
Generic Name	
Trade Name	
Manufacturer	
Dosage Form	

Briefly explain the advantages of this drug over those listed on the preferred list:

State which drug(s) on the preferred list this new drug could replace:

**Chairman of Drugs and Therapeutics Committee
Department of Pharmacy
Mid-Western Regional Hospital
Dooradoyle
Limerick**

